Sofinnova Investments Inc. Purchases 371,032 Shares of Jazz Pharmaceuticals PLC $JAZZ

Sofinnova Investments Inc. raised its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 63.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 959,860 shares of the specialty pharmaceutical company’s stock after buying an additional 371,032 shares during the period. Jazz Pharmaceuticals accounts for about 6.6% of Sofinnova Investments Inc.’s investment portfolio, making the stock its 3rd biggest position. Sofinnova Investments Inc.’s holdings in Jazz Pharmaceuticals were worth $163,176,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Cardinal Capital Management lifted its position in shares of Jazz Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after purchasing an additional 66 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Jazz Pharmaceuticals by 9.0% in the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 81 shares in the last quarter. UMB Bank n.a. increased its position in shares of Jazz Pharmaceuticals by 12.6% during the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 81 shares in the last quarter. Pinnacle Associates Ltd. increased its position in shares of Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after acquiring an additional 83 shares in the last quarter. Finally, Fairbanks Capital Management Inc. increased its position in shares of Jazz Pharmaceuticals by 0.4% during the third quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after acquiring an additional 94 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the sale, the director directly owned 384,682 shares of the company’s stock, valued at $73,281,921. The trade was a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president directly owned 51,549 shares in the company, valued at $11,950,604.67. The trade was a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 11,941 shares of company stock valued at $2,565,339. 4.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on JAZZ. Wells Fargo & Company raised their target price on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Robert W. Baird set a $252.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Sanford C. Bernstein restated a “market perform” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, June 9th. Bank of America raised their target price on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Finally, Barclays lifted their price objective on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Sixteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $246.06.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $230.59 on Tuesday. The stock has a market capitalization of $14.49 billion, a PE ratio of -11,523.74, a PEG ratio of 0.20 and a beta of 0.32. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. The firm has a 50 day moving average of $218.48 and a 200-day moving average of $189.25. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The company had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.